DeCure for Pituitary hormone deficiency, combined, 1
DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for pituitary hormone deficiency, combined, 1 — screening already-approved drugs against its 3-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePituitary hormone deficiency, combined, 1 maps to a 3-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for pituitary hormone deficiency, combined, 1 is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
POU class 1 homeobox 1 (POU1F1) — POU1F1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5WC9 · 3.15 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
The three review papers describe the molecular genetics of pituitary development, not a drug treatment. The 1993 paper reports that patients with pituitary dwarfism and variable hypothyroidism carry mutations in the Pit-1 gene, which activates transcription of growth hormone and prolactin genes and controls beta-TSH gene transcription. Inheritance of multiple pituitary hormone deficiency from Pit-1 mutations can be dominant or recessive depending on the mutant protein’s DNA binding properties. The 2006 review states that inherited forms of hormone deficiency arise from perturbations in the normal developmental program controlled by transcriptional regulators. The 2008 review lists recent basic discoveries including the roles of Pit-1 coactivators GATA-2 and TRAP-220 in TSHbeta regulation, a novel regulator Atbf1, and Wnt and Notch signalling in Prop-1-mediated cell lineage specification. Clinical advances cited are novel mutations in POU1F1 and PROP-1 genes and screening guidelines for patients with combined pituitary hormone deficiencies.
No drug, no intervention, no clinical trial data, no survival or response rates appear in any of these abstracts. The papers are exclusively reviews of developmental biology and genetic causes of the disease. There is no evidence of any drug being tested or repurposed for combined pituitary hormone deficiency type 1.
What is missing is any clinical trial testing a pharmacological agent for this condition, any patient outcome data from a treatment study, and any attempt to stratify patients by mutation type for a targeted therapy. The field remains at the stage of genetic diagnosis and developmental biology, with no therapeutic candidate yet advanced into human testing.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
American journal of diseases of children · 1983 · 33 citations
Acromegaly and Hyperprolactinemia in McCune-Albright Syndrome
AbstractIn a 21-year-old woman with McCune-Albright syndrome, acromegaly and hyperprolactinemia with hypopituitarism developed secondary to a large pituitary tumor. Bromocriptine suppressed the secretion of growth hormone and prolactin, with a reduction in tumor size. However, at the age of 8, she already showed evidence of biochemical acromegaly, with a paradoxical rise of growth hormone levels during two glucose tolerance tests, in the presence of a radiologically normal pituitary fossa. These data support the hypothesis that long-standing hypothalamic stimulation may have been responsible for the later development of a pituitary tumor.
Frontiers of hormone research · 2006 · 29 citations
Molecular Mechanisms of Pituitary Differentiation and Regulation: Implications for Hormone Deficiencies and Hormone Resistance Syndromes
AbstractDuring the last century, the questions posed by scientists and clinicians on pituitary function have led to new concepts about the mechanisms of hormone action and cell differentiation. In particular, the advent of molecular genetics and the cloning of pituitary hormone coding genes followed by discovery of their regulators during the last 20 years has provided tremendous insight into the pathophysiological bases of hormone deficit and excess, as well as offering novel therapeutic opportunities. Most insight was gained through the identification of transcription factors that control the program of pituitary organogenesis and cell differentiation; it is indeed the normal developmental program controlled by these transcriptional regulators that is perturbed in inherited forms of hormone deficiency. This review will summarize our current understanding of these processes and their implications for hormone deficiency and hormone resistance syndromes from a developmental perspective.
Journal of Clinical Medicine · 2024 · 29 citations · open access
An Update on Advances in Hypopituitarism: Etiology, Diagnosis, and Current Management
AbstractThis article provides an updated review of hypopituitarism (HP), an endocrine disorder characterized by a deficiency of one or more pituitary hormones. The various etiologies are reviewed, including pituitary neuroendocrine tumors (PitNETs), hypothalamic lesions, genetic mutations, and acquired factors such as head trauma, medications, neoplasms, and infiltrative diseases. It is noted that PitNETs are responsible for approximately half of the cases in adults, whereas in children the causes are predominantly congenital. Diagnosis is based on clinical evaluation and hormonal testing, with identification of the specific hormonal deficiencies essential for effective treatment. Laboratory tests present challenges and limitations that must be understood and addressed. Hormone replacement therapy is the mainstay of treatment, significantly improving patients' quality of life. It is important to know the possible interactions between hormone replacement therapies in HP. Recent advances in understanding the pathophysiology of HP and the importance of a multidisciplinary approach to the management of associated complications are discussed. This article emphasizes the need for comprehensive evaluation and continuous follow-up to optimize outcomes in patients with HP and highlights the importance of ongoing research to improve diagnostic and treatment strategies.
Journal of Pediatric Endocrinology and Metabolism · 1993 · 28 citations
Pit-1 and Pituitary Function
AbstractSeveral patients with pituitary dwarfism and a variable degree of hypothyroidism have been shown to have mutations in their Pit-1 gene. Pit-1 activates transcription of the growth hormone and prolactin genes and is necessary for the control of the beta-TSH gene transcription. The various mutations have different effects on the DNA binding and transactivating properties of Pit-1. Multiple pituitary hormone deficiency due to Pit-1 mutations is inherited either dominantly or recessively depending on the DNA binding properties of the mutant protein. The comparison of pheno- and genotype in patients with multiple pituitary hormone deficiency provides some insight into the function of the Pit-1 protein.
Current Opinion in Endocrinology Diabetes and Obesity · 2008 · 22 citations
Basic science and clinical research advances in the pituitary transcription factors: Pit-1 and Prop-1
AbstractPURPOSE OF REVIEW: The pituitary-specific transcription factors, Pit-1 (also called Pou1f1) and prophet of Pit-1 (Prop-1), are critical for normal pituitary development and function. The aim of the present review is to highlight the recent basic science and clinical research advances in these transcription factors, as they relate to signaling pathway interactions, gene regulation, and mutations in human diseases. RECENT FINDINGS: A number of important basic research discoveries have been made in the area of the pituitary-specific transcription factors, Pit-1 and Prop-1. Among these findings include: the effects of the Pit-1 coactivators, GATA-2 and TRAP-220, on the transcriptional regulation of the TSHbeta gene and thyrotropin expression, characterization of a novel pituitary regulator of Pit-1 expression, Atbf1, elucidation of the roles of Wnt and Notch signaling on Prop-1-mediated specification of the Pit-1 cell lineage and gonadotropes, and the identification of regulatory regions of the Prop-1 gene. Advances in clinical research include: the identification of novel mutations in the human POU1F1 and PROP-1 genes, and screening guidelines for patients with combined pituitary hormone deficiencies and possible mutations in these transcription factors. SUMMARY: Research into the complex interplay of signaling pathways and transcription factors that regulate the pituitary gland are important areas of developmental biology and normal physiology. Clinically, such research has important implications for human diseases by identifying inheritable transcription factor mutations that may cause pituitary hormonal deficiencies.
Archives of Internal Medicine · 1953 · 6 citations
CORTICOTROPIN (ACTH) AND ADRENAL HORMONES DURING OPERATIVE STRESS IN ENDOCRINE DISEASE
AbstractWIDESPREAD interest in the application of corticotropic and steroid hormone therapy to a diverse number of unrelated nonhormonal diseases has overshadowed the value of these drugs in endocrine disorders. This article deals with the more logical and specific application of the newer hormone preparations to endocrine deficiency states, with special emphasis on their value for protection against operative trauma. Poor response to surgical stress is a dominant feature of many deficiency states but is particularly significant in panhypopituitarism, Addison's disease, and functioning adrenal tumors with contralateral adrenal atrophy. <h3>PITUITARY DEFICIENCY</h3> Surgical therapy is a frequent necessity in the treatment of patients with pituitary failure, not only because the basic disease process often requires operative intervention, but also for the reason that these patients are subject to many of the surgical conditions which affect the endocrinologically normal population. Under conditions of stress, either incidental or coincidental to the basic glandular disease,
AbstractExcerpt Dr. Josiah Brown: The pace of new discoveries in medicine is constantly accelerating, and this is especially true in endocrinology. No sooner did we have adequate replacement therapy with the hormones of the target organs in pituitary insufficiency than we began to recognize some of the unique characteristics of human pituitary hormones—and then we found that there are certain special clinical situations in which only human pituitary hormones are adequate for clinical response. At this conference we shall review these three aspects and discuss two cases, the first one presented by Dr. Ament of the Department of Pediatrics. CASE PRESENTATIONS
Pathy's Principles and Practice of Geriatric Medicine · 2012 · 0 citations
The Pituitary Gland
AbstractPituitary disorders including tumours and hypopituitarism are not rare in older persons. Diagnosis is often delayed. Pituitary tumours respond well to either surgical, radiation or medical therapies. Hypopituitarism is treated by hormonal replacement. Treatment in older persons with diabetes insipidus involves desmopressin. Alterations in water metabolism are common.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
